Page last updated: 2024-12-10

13,14-dihydro-15-ketoprostaglandin d2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

13,14-dihydro-15-ketoprostaglandin D2 (13,14-dihydro-15-keto-PGD2) is a **metabolite of prostaglandin D2 (PGD2)**, a lipid mediator produced in the body that plays a role in various physiological processes.

Here's why it's important for research:

* **Marker of PGD2 metabolism:** 13,14-dihydro-15-keto-PGD2 is a stable and measurable metabolite of PGD2. Its presence in biological samples can be used to **infer the activity of PGD2** in different tissues or conditions.
* **Potential therapeutic target:** Studies suggest that 13,14-dihydro-15-keto-PGD2 may have **biological activity of its own**, independent of PGD2. For instance, it has been shown to **inhibit inflammation and pain** in some models.
* **Understanding PGD2 pathways:** Investigating the formation and breakdown of 13,14-dihydro-15-keto-PGD2 helps researchers **understand the complex metabolic pathways of PGD2**. This can shed light on how PGD2 exerts its effects and how its activity might be modulated.

**Here's a breakdown of its importance in specific areas of research:**

* **Allergy and asthma:** PGD2 plays a crucial role in allergic reactions, and 13,14-dihydro-15-keto-PGD2 is a key metabolite involved in its breakdown. Studying its formation and breakdown could lead to new therapeutic approaches for allergies and asthma.
* **Inflammation and pain:** Research suggests that 13,14-dihydro-15-keto-PGD2 might have anti-inflammatory and analgesic properties. This makes it a potential target for developing new pain relief therapies.
* **Cardiovascular disease:** Some studies indicate that 13,14-dihydro-15-keto-PGD2 may contribute to cardiovascular disease by affecting blood vessel function. Further research is needed to fully understand its role.

Overall, 13,14-dihydro-15-keto-PGD2 is an important molecule for research due to its connection to PGD2 metabolism, its potential therapeutic properties, and its role in understanding the intricate workings of PGD2 pathways.

13,14-dihydro-15-ketoprostaglandin D2: PGD2 metabolite; RN given refers to (5Z,9alpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5283036
CHEBI ID72603
SCHEMBL ID23352807
MeSH IDM0107104

Synonyms (28)

Synonym
dk-pgd2
13,14-dihydro-15-oxo pgd2
gtpl1900
dhk-pgd2
13,14-dihydro-15-keto-pgd2
LMFA03010022 ,
11,15-dioxo-9s-hydroxy-5z-prostenoic acid
13,14-dihydro-15-keto-prostaglandin d2
13,14-dihydro-15-oxo pgd-2
13,14-dihydro-15-ketoprostaglandin d2
59894-07-4
prost-5-en-1-oic acid, 9-hydroxy-11,15-dioxo-, (5z,9alpha)-
(z)-7-[(1r,2r,5s)-5-hydroxy-3-oxo-2-(3-oxooctyl)cyclopentyl]hept-5-enoic acid
13,14-dihydro-15-keto prostaglandin d2
15-oxo-13,14-dihydro-pgd2
9.alpha.-hydroxy-11,15-dioxo-prost-5z-en-1-oic acid
prost-5-en-1-oic acid, 9-hydroxy-11,15-dioxo-, (5z,9.alpha.)-
HMS3648M21
(5z,9alpha)-9-hydroxy-11,15-dioxoprost-5-en-1-oic acid
CHEBI:72603
13,14-dihydro-15-keto prostaglandin d2 lipid maps(r) ms standard
Q27070765
sr-01000946246
SR-01000946246-1
piperidine, 1-(4-methylphenyl)-
SCHEMBL23352807
mfcd00885499
PD020588

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response relations to PGD2 showed three distinct patterns: 1) a dose-dependent decrease in short-circuit current (Isc) at lower concentrations followed by a dose-dependent increase at higher concentrations; 2) dose-dependent decreases, with no increase even at the highest concentrations tested; and 3) dose-dependent increases in Isc, with no decreases at any concentration."( Biological activity of metabolites of PGD2 on canine proximal colon.
Betti, PA; Rangachari, PK, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
prostaglandins D
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
Eicosanoid metabolism via cyclooxygenases (COX)137
Arachidonic acid (AA, ARA) oxylipin metabolism076
Arachidonic acid metabolism via COX (Cyclooxygenase) pathway035

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1346326Human DP2 receptor (Prostanoid receptors)2003The Journal of pharmacology and experimental therapeutics, Aug, Volume: 306, Issue:2
Expression and molecular pharmacology of the mouse CRTH2 receptor.
AID1346401Mouse DP2 receptor (Prostanoid receptors)2005The Journal of biological chemistry, Sep-16, Volume: 280, Issue:37
Identification of determinants of ligand binding affinity and selectivity in the prostaglandin D2 receptor CRTH2.
AID1346326Human DP2 receptor (Prostanoid receptors)2005European journal of pharmacology, Nov-07, Volume: 524, Issue:1-3
CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist responses.
AID1346401Mouse DP2 receptor (Prostanoid receptors)2003The Journal of pharmacology and experimental therapeutics, Aug, Volume: 306, Issue:2
Expression and molecular pharmacology of the mouse CRTH2 receptor.
AID1346326Human DP2 receptor (Prostanoid receptors)2002British journal of pharmacology, Dec, Volume: 137, Issue:8
Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (9.52)18.7374
1990's1 (4.76)18.2507
2000's12 (57.14)29.6817
2010's6 (28.57)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.44 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index5.54 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]